|
|
Post by trenddiver on Jun 11, 2015 19:26:39 GMT -5
Time to call a spade a spade. I like many other long term longs was ecstatic when the share price recently skyrocketed. Then of course I now feel dejected because the share price dropped again. We can look for people or to put the blame on - Af, Cramer, Matt, Sanofi, but it's time to put the blame where it belongs and that is on ourselves and management.
I say ourselves, because we greedily enable the short sellers by loaning them our shares to short and to Mannkind for keeping us in the dark and for being inept in dealing with Wall Street.
The truth is, except for a possible short squeeze, there was no reason for MNKD's shares to go up in the first place. Nothing had changed materially in the launch of Afrezza, it is still pitifully slow. Change is scary. It's looks like doctors are more scared of change than patients and there are many obstacles and impediments in the way. We all know what they are. It's a great technology, but sometimes technology is too far ahead of its time to be successful in the marketplace. Based on what I see, it's going to be slow, slow, slow. So slow, that I don't even know how you measure success. Only time will tell. Right now, Afrezza and Mannkind are at the mercy of Sanofi and its ability to educate doctors and patients about Afrezza's benefits.
Management unwillingness to explain much about the future Technosphere applications leaves retail and institutional investors in an information vacuum. I understand management's need to play it close to vest to protect the IP, but at the same time, management is basically saying, trust us - we know what we are doing. They throw out words like "blockbuster", to keep us enthused. Ask yourself, are there any other companies you would be investing in where you don't really understand what going on? I for sure would not. I'm here because of Al Mann, but he's now in the background. We can only hope that he's still in charge.
One last thing, Matt and Hakan and repeatedly proven that they are too unsophisticated to deal with the Wall Street gang. No retail or institutional investor can be happy when the share price drops 20% or more every time they open their mouth. We investors expect management not only to manage the company's affairs, but also the company's perception on Wall Street.
Trend
|
|
|
|
Post by notamnkdmillionaire on Jun 11, 2015 19:51:40 GMT -5
Time to call s spade a spade. I like many other long term longs was ecstatic when the share price recently skyrocketed. The of course I feel dejected because the share price dropped again. And then we look for people or others to put the blame on. Af, Cramer, Matt, Sanofi, Mannkind. I have already said I blame Spiro for coming home too soon from his cruise! The stock price was on a tear while he was eating and drinking his way through Europe like a Roman Emperor. Once he got home, the stock tanked. Maybe we could put together a crowd fund raiser to get him back on a cruise? Sounds good, right?  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 11, 2015 20:55:36 GMT -5
Trend, what if takes 5 years to hit $1 billion in sales? Would you be ok with that? Trying to gauge what your version of "slow" is.
|
|
|
|
Post by trenddiver on Jun 11, 2015 21:52:52 GMT -5
Trend, what if takes 5 years to hit $1 billion in sales? Would you be ok with that? Trying to gauge what your version of "slow" is. Truth be told, my patience is running low. I'm holding 25k shares plus 26k $3.00 Jan 2017 calls, all told worth about $200k. Unless by year end, I see a progress with Afrezza (more markets, more scripts, label changes), plus more clarity on Technosphere future activities, I'll be reducing my exposure to MNKD. There are plenty of other biotech stocks that I currently own and like that have equally good prospects going forward. It's hard to fight the powerful short interests supported by shareholders that enable the short activity, a difficult sell in a highly competitive market place, and current management who are uninspiring and unsophisticated in the ways of Wall Street. I am willing to invest in "hope" only so long. Trend |
|
|
|
Post by orlon on Jun 11, 2015 22:04:02 GMT -5
Trend, I agree completely. The fact that short sales are driving the stock price down when in fact many contribute to the stock pounding and complain about the low PPS makes little sense to me. Edstrom does not appear to me to be CEO material. This was even more apparent at the GS 'interview' with the same analyst who slammed the company just three months ago. He should have sent a note declining the opportunity to explain anything to Olson...his, Olson's, mind was made up already. Mannkind needs a leader, not just someone with tenure. I give the company another six months to pull up their socks and be a partner to Sanofi rather than the mouse in the corner.
|
|
|
|
Post by peppy on Jun 12, 2015 3:25:58 GMT -5
Calling a spade a spade. A lot of money working at status quo. You eat Doritos and Cheetos, through in a milk dud and your fasting glucose is going to be higher than 100. You are a type two diabetic. What a set up. Type 1: Who knew? We were sold, told, You could inject insulin. Enter continuous glucose monitoring. Now we can SEE how insulin subq really works on blood glucose levels. When it works. How it works. It looks like a roller coaster. Enter the continuous glucose monitoring and Afrezza, I see better control. I see ease of control. I am familiar with blood glucose and blood glucose monitoring. I asked a nurse working in a hospital if she was familiar with HgA1c. She said she was not, that in the hospital they use a finger prick blood glucose monitor. Blood glucose monitor for acute. HbA1c is used more for chronic care now that this measure has been created and established. Spiros fasting blood sugars the ones posted are perfect. screencast.com/t/WZkIT2ikn7l |
|
|
|
Post by luke233 on Jun 12, 2015 8:12:06 GMT -5
i don't know what price you purchased at but double (triple maybe) your money in a few years is pretty easily obtainable with mnkd. Where else exactly are you going to get that kind of return? You'd be lucky to get 10% / year.
And yeah stocks with upside have high downside... How did you amass 200k to invest by being emotional?
|
|
|
|
Post by tbone on Jun 12, 2015 8:19:41 GMT -5
Time to call a spade a spade. I like many other long term longs was ecstatic when the share price recently skyrocketed. Then of course I now feel dejected because the share price dropped again. We can look for people or to put the blame on - Af, Cramer, Matt, Sanofi, but it's time to put the blame where it belongs and that is on ourselves and management. I say ourselves, because we greedily enable the short sellers by loaning them our shares to short and to Mannkind for keeping us in the dark and for being inept in dealing with Wall Street. The truth is, except for a possible short squeeze, there was no reason for MNKD's shares to go up in the first place. Nothing had changed materially in the launch of Afrezza, it is still pitifully slow. Change is scary. It's looks like doctors are more scared of change than patients and there are many obstacles and impediments in the way. We all know what they are. It's a great technology, but sometimes technology is too far ahead of its time to be successful in the marketplace. Based on what I see, it's going to be slow, slow, slow. So slow, that I don't even know how you measure success. Only time will tell. Right now, Afrezza and Mannkind are at the mercy of Sanofi and its ability to educate doctors and patients about Afrezza's benefits. Management unwillingness to explain much about the future Technosphere applications leaves retail and institutional investors in an information vacuum. I understand management's need to play it close to vest to protect the IP, but at the same time, management is basically saying, trust us - we know what we are doing. They throw out words like "blockbuster", to keep us enthused. Ask yourself, are there any other companies you would be investing in where you don't really understand what going on? I for sure would not. I'm here because of Al Mann, but he's now in the background. We can only hope that he's still in charge. One last thing, Matt and Hakan and repeatedly proven that they are too unsophisticated to deal with the Wall Street gang. No retail or institutional investor can be happy when the share price drops 20% or more every time they open their mouth. We investors expect management not only to manage the company's affairs, but also the company's perception on Wall Street. Trend So the stock is up 70% in a month and right where it was a week ago. A week ago 5.70 was making everyone giddy. Today it draws comments like this. The fact is mnkd is a volatile stock. It always has been. There are polar opposite views of Afrezza. Obstacles are nothing new to this company and they have been overcome as they have presented themselves in the past. This thread should be called, "I feel like whining". Maybe then all whining can take place here so those that don't want to read it can avoid it. |
|
|
|
Post by kc on Jun 12, 2015 8:56:20 GMT -5
Do you really think that any of the longs who have loaned their shares out to the Shorts can move the needle? There are a 118 Million shorts. How many shares do you think US retail longs on this board or any other board control? Why shouldn't we get some kind of return for our invested capital until some event happens like a Buy In by Sanofi. Many of us have shares that we are upside down in so getting some interest income helps us bide the time until there is a positive event in PPS. Time to call a spade a spade. I like many other long term longs was ecstatic when the share price recently skyrocketed. Then of course I now feel dejected because the share price dropped again. We can look for people or to put the blame on - Af, Cramer, Matt, Sanofi, but it's time to put the blame where it belongs and that is on ourselves and management. I say ourselves, because we greedily enable the short sellers by loaning them our shares to short and to Mannkind for keeping us in the dark and for being inept in dealing with Wall Street.
. No retail or institutional investor can be happy when the share price drops 20% or more every time they open their mouth. We investors expect management not only to manage the company's affairs, but also the company's perception on Wall Street. Trend
Getting 32% interest seems like an amount out of the TV show AMERICAN GREED. where is Stacey Keech. I can hear his voice telling us its too good to be true.
|
|
|
|
Post by Chris-C on Jun 12, 2015 9:05:58 GMT -5
Time to call a spade a spade. I like many other long term longs was ecstatic when the share price recently skyrocketed. Then of course I now feel dejected because the share price dropped again. We can look for people or to put the blame on - Af, Cramer, Matt, Sanofi, but it's time to put the blame where it belongs and that is on ourselves and management. I say ourselves, because we greedily enable the short sellers by loaning them our shares to short and to Mannkind for keeping us in the dark and for being inept in dealing with Wall Street. The truth is, except for a possible short squeeze, there was no reason for MNKD's shares to go up in the first place. Nothing had changed materially in the launch of Afrezza, it is still pitifully slow. Change is scary. It's looks like doctors are more scared of change than patients and there are many obstacles and impediments in the way. We all know what they are. It's a great technology, but sometimes technology is too far ahead of its time to be successful in the marketplace. Based on what I see, it's going to be slow, slow, slow. So slow, that I don't even know how you measure success. Only time will tell. Right now, Afrezza and Mannkind are at the mercy of Sanofi and its ability to educate doctors and patients about Afrezza's benefits. Management unwillingness to explain much about the future Technosphere applications leaves retail and institutional investors in an information vacuum. I understand management's need to play it close to vest to protect the IP, but at the same time, management is basically saying, trust us - we know what we are doing. They throw out words like "blockbuster", to keep us enthused. Ask yourself, are there any other companies you would be investing in where you don't really understand what going on? I for sure would not. I'm here because of Al Mann, but he's now in the background. We can only hope that he's still in charge. One last thing, Matt and Hakan and repeatedly proven that they are too unsophisticated to deal with the Wall Street gang. No retail or institutional investor can be happy when the share price drops 20% or more every time they open their mouth. We investors expect management not only to manage the company's affairs, but also the company's perception on Wall Street. Trend So the stock is up 70% in a month and right where it was a week ago. A week ago 5.70 was making everyone giddy. Today it draws comments like this. The fact is mnkd is a volatile stock. It always has been. There are polar opposite views of Afrezza. Obstacles are nothing new to this company and they have been overcome as they have presented themselves in the past. This thread should be called, "I feel like whining". Maybe then all whining can take place here so those that don't want to read it can avoid it. Actually, the idea of a thread for skittish, tired, or frustrated investors to sound off is not a bad idea. Lending shares to the shorts and then complaining about the drop in share price sounds like a fool's game to me, but I don't blame people for trying to get a return on their investment dollars. There are very few worthwhile high return investments where a person can sit on the porch and drink lemonade while returns flow in without feeling the pressure of risk. Anxiety, discomfort and insomnia are part of the journey for people not seeing the big picture or having unrealistic expectations. And, as for the drumbeat of criticism around the executive team; one also notices that this tends to correlate with the movement of the share price. Actually, no CEO is without blemish; and Hakan, who is relatively new to his role, still knows well that what matters is execution. Afrezza got approved, a partnership with a 5 star global pharma got signed, scripts have started flowing in, and other drugs are in the pipeline. It's been said repeatedly that building this into a blockbuster will take 2-3 years, and involve overcoming multiple challenges; yet progress is reported on all fronts. As long as the short position continues to be large and as long as FUD can be spread, we will continue to see the volatility we see. So from my porch, I see a road being built, and drivers screaming about the delays and the uneven pavement. But I know that once that pavement is laid, there will be happy faces and smooth rides moving across my field of view. So, I'm happy to watch the commotion, lean back, smile, and pour myself another glass of lemonade. The drug and technology will be successful. Chris C |
|
|
|
Post by mnholdem on Jun 12, 2015 10:09:56 GMT -5
Hakan and Matt wouldn't need to be so 'Wall Street savvy' if the sales numbers were higher. While I agree to some extent that a seasoned presenter may give MannKind a little more polish, well, a rose by any other name is a rose. What smells at the present moment is that, compared to the nearly 300k weekly TRx scripts for RAA's, Afrezza has virtually no sales to boast. It's these numbers that are at the root of our unrest. Add to this the not-so-simple fact that Sanofi probably gags MNKD management as to what it can disclose and my perception of Hakan is that his leadership abilities are just fine. When Afrezza sales reach what investors' consider to be 'satisfactory levels' and share price is in the teens, MNKD investors and traders won't be so critical, I think.
Matt stated in effect that, "based on our forecasts, we will 'get there' pretty quickly, but I'm uncomfortable saying anything else." [paraphrased] I'm not certain what Matt means by "get there" - perhaps the level they planned to be at, of which he mentions being eights weeks behind. He does predict higher share prices by August...also his comment might be related to the convertible debt, but I really think he's expected much better Afrezza sales figures.
We'll get there but, damn, this has been about as exciting as watching grass grow. I guess that would be calling a blade a blade (chuckle).
Good fortune all.
|
|
|
|
Post by hankscorpio7 on Jun 12, 2015 10:19:58 GMT -5
Tbone- you didn't have to read it.
You have a decent amount invested Trend. The grass is always greener... Seems like you are looking for more performance this year. Can't fault you for that. So, is MNKD more likely to increase? Barring a huge, unexplained uptick in scripts, the only thing on horizon now is the DTC. Sad, but true. We can thank management for telling us straight- and what could they say at GS?. Will the DTC be able to use patient results not included in a clinical trial? Patients, docs need to know why it is superior to really drive scripts and I have a hard time seeing where the hook will be in traditional ads without new trials. Even if ads work, newly informed diabetics, could take 2-3 months to get in script count. It doesn't look good for yearly forecast. But next year...
How excited investors are about a stock usually correlates to amount of portfolio they put at risk. Mnkd is my largest position but that is more a reflection of my interpretation of the overall market. It has gone from 60% to less then 10% of my portfolio. I sleep well. You seem to be at a similar stage regarding thoughts on MNKD, I would recommend getting to that level of investment. Good luck if you use your MNKD money elsewhere, hope AF doesn't launch a tirade against whatever your new love may be. A bird in the hand is.. probably pecking you and pooping all over.
|
|
|
|
Post by scottiemac on Jun 12, 2015 10:23:49 GMT -5
All those RAAs with hundreds of thousands of scripts did NOT have that level at the same stage as Afrezza. Face it, they've been out there much, much longer, some for years. Of course they will have far more than MNKD. And it's a more crowded field - practically tripping over products, new and old, for the treatment of some aspect of diabetes. It takes time, for name recognition, for initial prescribing, feedback from patients, testing and reviewing and publishing of results of Afrezza "in the wild" so to speak and then peer-reviewed studies of improved A1C levels etc. Meanwhile we rumble along like the little engine that could.
Saw my internist yesterday for a general check-up. Had a fasting BG this morning because my February results were elevated into the 170s (normally run low 100s, occasionally 90-something), but I was also sick at the time which could have screwed up the readings. Anyway, the discussion of possible DM came up and treatment. She generally starts with oral meds, Metformin was mentioned. I asked if she had heard of Afrezza and she had (score one for us) and had heard good things about it (ditto) but clearly needed more education on the topic. She wasn't sure how many of their patients would be able to take it because they have a fair number of patients with COPD. I told her I'd shoot her some links to more information via the patient portal. LOVE those - can get my lab results as soon as entered, set up appointments, get refills etc, all online.
|
|
|
|
Post by suebeeee1 on Jun 12, 2015 10:49:49 GMT -5
The analogy of building a highway is perfect! While the road is built, some people begrudgingly travel and fight traffic every day, some take alternate routes and some car-share to make the commute easier.
Therefore, I don't begrudge anyone who loans out their shares to make the ride easier, or those who sell at the top of each bump up and buy again at the bottom.
Those who just buy and hold are making the commute each day in miserable conditions. They complain or not, but the make the commute.
In the end, it will all be good. Since I am in the commute as well and can't join you for a lemonade, I'll just waive as I pass you sitting on your porch.
|
|
|
|
Post by ripano on Jun 12, 2015 11:54:35 GMT -5
Actually a lot has changed in recent months. First of all we saw a huge investment fund BUY so many shares of MNKD that they had to file a 5.1c with SEC. That alone is epic.
We we have also been fortunate enough to have a guys like Sam Finta organize diabetics to show their personal weekly sugar levels dropping to near non diabetic levels. Epic
We know that lines 2-3 will be approved very soon. Epic
We know DTC advertising starts in July. Epic
Doctors who attended ADA conference I am sure were very impressed in the pharmakinetcs of Afrezza. Indeed many of them will finally start to prescribe it to their patients very soon. Epic
And last but certainly not least. Step back a second and ask yourself why big money institutional accounts continue to BUY ? I have said several times that in my opinion shorts also included BUYERS who kept price down to continue to accumulate. We are nearing the short covering to actually begin due to the success of Afrezza with current users and the countless consumers who will know shortly about it and ask their doctors who now finally I hope have the confidence to start prescribing it to their patients. This is truly a descriptive technology for other Pharmas who sell injectable insulin. And now throw in new products being worked on and you have a true Mega Blockbuster of a company. We have been fortunate to have been able to continue to buy and in my case lower my cost in this amazing investment opportunity. All is well.
|
|
